FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

• Status: Recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the conversion therapy of right-sided colon cancer liver metastases

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University
• Treatments: Bevacizumab; Cetuximab

Criteria

Inclusion Criteria:

• ECOG perfomance 0-1

• pathologically confirmed colorectal carcinoma, with RAS wild type

• inital unresectable liver metastases discussed by MDT

• prior no systemical therapy or exceed 6 months after the adjuvant chemotherapy of primary tumor surgery.

• without extraheptic metastatic lesions, except for locally controlled lung metastases (RFA or SBRT)

• adequate blood, liver and renal function

• expected survival longer than 6 months

Exclusion Criteria:

• with bleeding risk

• interestinal obstruction or disease

• uncontrolled hypertension and severe heart disease

• previous severe thrombotic events

• central nervous system metastases

• accompanied with other malignant tumor